Causeway Therapeutics
@causewaytx.bsky.social
We are The Tendon Health Company, a clinical-stage biotech developing novel medicines for tendon disease. www.causewaytx.com
#ICYMI, we debuted data from our Phase 2 trial of TenoMiR® in lateral epicondylitis, showing for the 1st time that a miR29a therapy relieves symptoms & improves tendon healing when correctly delivered into the tendinopathic lesion.
Read our release: bit.ly/4nC58IE
Read our release: bit.ly/4nC58IE
October 28, 2025 at 11:12 AM
#ICYMI, we debuted data from our Phase 2 trial of TenoMiR® in lateral epicondylitis, showing for the 1st time that a miR29a therapy relieves symptoms & improves tendon healing when correctly delivered into the tendinopathic lesion.
Read our release: bit.ly/4nC58IE
Read our release: bit.ly/4nC58IE
Did you know that each year more than 11 million people in the US experience symptoms of tendinopathy?
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
July 31, 2025 at 1:44 PM
Did you know that each year more than 11 million people in the US experience symptoms of tendinopathy?
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
Did you see Causeway’s new website?
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
June 4, 2025 at 1:20 PM
Did you see Causeway’s new website?
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Meet Derek Gilchrist, PhD, Causeway’s Co-founder and Chief Science Officer. He leads the scientific development of TenoMiR®, a therapeutic now in a phase 2 clinical trial for patients with lateral epicondyle tendinopathy (tennis elbow). Learn more here: www.causewaytx.com
May 20, 2025 at 7:24 PM
Meet Derek Gilchrist, PhD, Causeway’s Co-founder and Chief Science Officer. He leads the scientific development of TenoMiR®, a therapeutic now in a phase 2 clinical trial for patients with lateral epicondyle tendinopathy (tennis elbow). Learn more here: www.causewaytx.com
Our CEO Derek Gilchrist was recently featured in “Scrip Asks What Does 2025 Hold for Biopharma?” Check out the full article for Derek’s insights on how new approaches to microRNA delivery have the potential to target the root cause of disease: bit.ly/3FjJHvq
March 12, 2025 at 2:42 PM
Our CEO Derek Gilchrist was recently featured in “Scrip Asks What Does 2025 Hold for Biopharma?” Check out the full article for Derek’s insights on how new approaches to microRNA delivery have the potential to target the root cause of disease: bit.ly/3FjJHvq